Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Fecobionics in Biofeedback Therapy in Dyssynergia Patients

NCT05807321 · View on ClinicalTrials.gov ↗

Study Summary

Constipation affects 12-19% of Americans. Pelvic floor dyssynergia is considered to play an important role in constipation but the underlying mechanisms are not well understood in individual patients. The investigators have developed a novel device named Fecobionics that provide detailed mapping of physiological parameters during defecation. The aim of the study is to use Fecobionics to assess anorectal function in dyssynergia patients and monitor and predict the outcome of the biofeedback therapy.

Conditions Studied

Interventions

  • DEVICE Fecobionics

Study Locations (2)

California

  • California Medical Innovations Institute — San Diego

Georgia

  • Digestive Health Center- Augusta University — Augusta

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2023-10-03
Est. Completion 2027-03-31
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05807321

The ClinicalTrials.gov registry entry for NCT05807321 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The California Medical Innovations Institute, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Constipation appearing as the primary indexed condition, and to 1 intervention — of which Fecobionics is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05807321 reports 2 study locations spanning 2 distinct geographic areas — top geographies include California, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05807321 about?

NCT05807321 is a clinical study titled "Fecobionics in Biofeedback Therapy in Dyssynergia Patients". Constipation affects 12-19% of Americans. Pelvic floor dyssynergia is considered to play an important role in constipation but the underlying mechanisms are not well understood in individual patients. The investigators have developed a novel device named Fecobionics that provide detailed mapping of ...

What is the current status of trial NCT05807321?

This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2023-10-03. Estimated completion is 2027-03-31.

What conditions does trial NCT05807321 study?

This clinical trial studies the following conditions: Constipation, Dyssynergia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05807321?

The interventions under investigation include: Fecobionics (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05807321?

This trial is sponsored by The California Medical Innovations Institute, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05807321 being conducted?

This trial has 2 study locations across California, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial